Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Tax Provisions (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Tax Provisions data on record, last reported at $767000.0 in Q4 2025.

  • For Q4 2025, Tax Provisions rose 233.16% year-over-year to $767000.0; the TTM value through Dec 2025 reached $1.9 million, up 87.96%, while the annual FY2025 figure was $1.9 million, 87.96% up from the prior year.
  • Tax Provisions reached $767000.0 in Q4 2025 per MIRM's latest filing, up from -$262000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.0 million in Q1 2025 and bottomed at -$6.6 million in Q2 2022.
  • Average Tax Provisions over 5 years is -$120600.0, with a median of $170500.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: plummeted 59827.27% in 2022, then soared 1815.38% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $12000.0 in 2021, then skyrocketed by 1066.67% to $140000.0 in 2022, then surged by 60.71% to $225000.0 in 2023, then plummeted by 356.0% to -$576000.0 in 2024, then soared by 233.16% to $767000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $767000.0 in Q4 2025, -$262000.0 in Q3 2025, and $402000.0 in Q2 2025.